Lineage Cell Therapeutics, Inc. LCTX
1.13 USD +0.08 (+8.17%)
Nov 11, 2026, 3:53 PM EST
1.00 Day range 1.13
0.88 52-week range 1.99
- YTD
- -32.63%
- 1 year
- -38.19%
News
benzinga.com Transcript: Lineage Cell Therapeutics Q2 2026 Earnings Conference Call On Thursday, Lineage Cell Therapeutics (AMEX:LCTX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by…
benzinga.com Lineage Cell Therapeutics Updates COR1 Corneal Cell Transplant Program; Highlights Scalable Allogeneic Production Via AlloSCOPE Platform And Plans Conference Call Today Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PTCOR1 Aims to Provide an "Off the Shelf" Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial DiseaseUtilizes…- benzinga.com Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call On Tuesday, Lineage Cell Therapeutics (AMEX:LCTX) discussed first-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to…
benzinga.com Lineage Cell Therapeutics Q1 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.725M Miss $3.602M Estimate Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of…
benzinga.com Earnings Scheduled For May 12, 2026 
benzinga.com Service Properties Trust, ConocoPhillips And Other Big Stocks Moving Lower In Monday's Pre-Market Session US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market trading. Other decliners: MGRT, UP, CDZI, LCTX, KEP, AUTL, EOG, ANGX, COP.
benzinga.com HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.
benzinga.com Lineage Cell Therapeutics Expands Cell Transplant Pipeline With COR1 New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing ExpertiseFuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Lineage Cell Therapeutics Files Prospectus To Offer Up To $100M In Common Shares, Preferred Shares, Debt, And Warrants $100,000,000 Common SharesPreferred SharesDebt SecuritiesWarrants From time to time, we may offer up to $100,000,000 of any combination of the securities described in this prospectus in one or more…
- benzinga.com Lineage Cell Therapeutics Files $60M ATM Share Offering Prospectus Supplement Other Events.On March 11, 2026, Lineage Cell Therapeutics, Inc. (the "Company") filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement dated March 11, 2026 (the…
- benzinga.com D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Raises Price Target to $3 D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and raises the price target from $2 to $3.
benzinga.com Lineage Cell Therapeutics Q4 Earnings Summary & Key Takeaways 
benzinga.com Lineage Cell Therapeutics Q4 EPS $0.00 Beats $(0.05) Estimate, Sales $6.600M Beat $2.577M Estimate Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.05) by 108.51 percent. This is a 120 percent increase over losses…- benzinga.com Earnings Scheduled For March 5, 2026
benzinga.com A Look Ahead: Lineage Cell Therapeutics's Earnings Forecast 
benzinga.com Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - benzinga.com D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Lineage Cell Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Joseph Pantginis maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.
- benzinga.com Lineage Cell Therapeutics Sold 12M Common Shares To Janus Henderson Investors At A Purchase Price Of $1.75/Share In A Block Transaction Under Its ATM Offering Program; Company Received $21M In Gross Proceeds On November 12, 2025, Lineage Cell Therapeutics, Inc. (the "Company") sold 12,000,000 common shares to Janus Henderson Investors at a purchase price of $1.75 per share in a block transaction under…
- benzinga.com Lineage Cell Therapeutics Q3 EPS $(0.13) Misses $(0.02) Estimate, Sales $3.681M Beat $2.300M Estimate Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.02) by 441.67 percent. This is a 550 percent decrease over…
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Lineage Cell Therapeutics Announces Launch Of A New Islet Cell Transplant Program Targeting Type 1 Diabetes Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions,…
- benzinga.com 5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know
benzinga.com D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.- benzinga.com Lineage And William Demant Collaborate Through Investment To Develop ReSonance For Hearing Loss Three-year term intended to advance preclinical development of ReSonanceUp to $12 million of development costs to be contributed by William Demant Invest
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.- benzinga.com Update: Lineage Cell Therapeutics Q2 Adj. EPS $(0.07) Misses $(0.03) Estimate, Sales $2.765M Beat $1.472M Estimate Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 159.26 percent. This is a 133.33 percent decrease over…
benzinga.com Lineage Cell Therapeutics Q2 EPS $(0.13) Misses $(0.03) Estimate, Sales $2.765M Beat $1.472M Estimate Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.03) by 348.28 percent. This is a 333.33 percent decrease over…- benzinga.com Earnings Scheduled For August 12, 2025
- benzinga.com A Peek at Lineage Cell Therapeutics's Future Earnings
- benzinga.com D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.
- benzinga.com Lineage Cell Therapeutics Announced The First Chronic Spinal Cord Injury Patient Has Been Treated In The Company's DOSED Clinical Study, Evaluating A New Parenchymal Spinal Delivery System The DOSED study is designed to evaluate the safety and utility of a new parenchymal spinal delivery system, a novel delivery device developed to deliver OPC1 directly to the site of injury in…
- benzinga.com D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.
benzinga.com Two Biotech Stocks Poised For Big Moves On Monday - benzinga.com HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.
- benzinga.com Lineage's OpRegen Shows +9 Letter BCVA Gains At 3 Years With Extensive Cell Coverage In Phase 1/2a Trial For Geographic Atrophy Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion siteEvidence of retinal structural improvement persisted out to 3…
- benzinga.com Lineage Cell Therapeutics Q1 EPS $(0.02) Beats $(0.03) Estimate, Sales $1.50M Miss $1.87M Estimate Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 50 percent increase over losses…
- benzinga.com Earnings Scheduled For May 13, 2025
- benzinga.com Examining the Future: Lineage Cell Therapeutics's Earnings Outlook
- benzinga.com Lineage Cell Therapeutics Says RG6501 Phase 1/2a Clinical Study 36 Month Results To Be Featured At Clinical Trials At The Summit 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that…
- benzinga.com Lineage Cell Therapeutics And Christopher & Dana Reeve Foundation To Collaborate And Present 3Rd Annual Spinal Cord Injury Investor Symposium Fully Virtual Event Scheduled for June 27, 2025Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com B. Riley Securities Maintains Buy on Lineage Cell Therapeutics, Lowers Price Target to $3 B. Riley Securities analyst Mayank Mamtani maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and lowers the price target from $4 to $3.
- benzinga.com Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock
- benzinga.com D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.